Alison Margaret Dunning
Has grant
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Understanding how DNA variants confer an increased breast cancer risk
Open Date: 2014-01-01
Close Date: 2016-12-31
Grant: Close
Functional Analysis of Breast Cancer Risk Regions
Open Date: 2014-01-01
Close Date: 2016-12-31
Grant: Close
Identifying genetic variants that increase risk of endometrial and other cancers in the general population
Open Date: 2012-01-01
Close Date: 2014-12-31
Grant: Close
Understanding how specific DNA sequences can increase the risk of breast cancer
Open Date: 2012-01-01
Close Date: 2014-12-31
Grant: Close
Genetic Epidemiology of Cancer Sample Handling, Genotyping & Mutation Detection Core
Open Date: 2008-10-01
Close Date: 2013-09-30
Articles (3)
Purpose: Genome-wide association studies are the gold standard for identifying SNP associated with rectal toxicity after prostate cancer radiotherapy. However, they often neglect the radiotherapy dose distribution, which is a key contributor to toxicity risk. Here, we combined rectal dose surface maps with genetic data to identify rectal regions in which variants influence dose–toxicity relationships. Experimental Design: Data were analyzed from 1,293 patients with prostate cancer from the REQUITE study. Deep learning rectum contouring ensured consistent segmentation, and rectum lengths were standardized to generate two-dimensional dose surface maps. Patients were categorized based on the presence of risk alleles for three candidate SNP (rs1801516, rs17055178, and rs17630638). Propensity score matching accounted for age, rectal volume, prostate volume, and hormone therapy. Voxel-wise Cox proportional hazards models with permutation testing assessed dose–toxicity associations. Results: Voxel-wise Cox proportional hazards models revealed significant ( P Conclusions: This study identified genotype-driven toxicity patterns using spatial dose mapping. By revealing consistent high-risk rectal regions, this approach strengthens the link between genomics and radiotherapy planning. Importantly, modern radiotherapy planning makes it feasible to reduce dose in genetically sensitive patients and move toward more personalized treatment.
Year:
2025
Background: Risk estimates for women carrying germline mutations in breast cancer susceptibility genes are mainly based on studies of European ancestry women. Methods: We investigated associations between pathogenic variants (PV) in 34 genes with breast cancer risk in 871 cases [307 estrogen receptor (ER)-positive, 321 ER-negative, and 243 ER-unknown] and 1,563 controls in the Ghana Breast Health Study (GBHS), and estimated lifetime risk for carriers. We compared results with those for European, Asian, and African American ancestry women. Results: The frequency of PV in GBHS for nine breast cancer genes was 8.38% in cases and 1.22% in controls. Relative risk estimates for overall breast cancer were: (OR, 13.70; 95% confidence interval (CI), 4.03–46.51) for BRCA1 , (OR, 7.02; 95% CI, 3.17–15.54) for BRCA2 , (OR, 17.25; 95% CI, 2.15–138.13) for PALB2 , 5 cases and no controls carried TP53 PVs , and 2.10, (0.72–6.14) for moderate-risk genes combined ( ATM, BARD1, CHEK2, RAD51C, RAD52D ). These estimates were similar to those previously reported in other populations and were modified by ER status. No other genes evaluated had mutations associated at P BRCA1 , BRCA2 , and PALB2 and moderate-risk genes were 18.4%, 9.8%, 22.4%, and 3.1%, respectively, markedly lower than in Western populations with higher baseline risks. Conclusions: We confirmed associations between PV and breast cancer risk in Ghanaian women and provide absolute risk estimates that could inform counseling in Ghana and other West African countries. Impact: These findings have direct relevance for breast cancer genetic counseling for women in West Africa.
Year:
2025
Background: Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively affects survivors. Few risk factors are known beyond the radiation dose and volume of bladder exposed. A polygenic risk score (PRS) could identify susceptible patients. Methods: A PRS was built using genome-wide association results from the Radiogenomics Consortium ( N = 3,988) and then tested in the prospective REQUITE and URWCI studies ( N = 2,034). The primary outcome was time to patient–reported gross [grade ≥2, (≥G2)] hematuria, analyzed using Cox proportional hazards regression. Secondary outcomes were ≥G2 urinary retention and frequency. The PRS was externally validated for clinically diagnosed irradiation cystitis in the UK Biobank ( N = 8,430). A gene-burden test evaluated rare coding variants. Results: A 115-variant PRS was associated with a significantly increased risk of ≥G2 hematuria [hazard ratio (HR) per SD = 1.22; P = 0.009] as well as urinary retention (HR per SD = 1.18; P = 0.016) and frequency (HR per SD = 1.14; P = 0.036). When binarized, men in the upper decile (PRS high ) had a >2-fold increased risk of hematuria after adjusting for clinical risk factors [HR = 2.12; P = 0.002; Harrel’s concordance index = 0.71 (95% confidence interval, 0.65–0.76)]. A similar effect size was seen in the UK Biobank for clinically diagnosed irradiation cystitis [odds ratio (OR) = 2.15; P = 0.026]. The burden test identified BOD1L1 as a putative novel radiosensitivity gene. Conclusions: This PRS identifies susceptible patients and could guide the selection of those needing reoptimized treatment plans that spare the bladder beyond currently recommended constraints. Impact: PRS-guided treatment planning in radiation oncology could lower the incidence of clinically relevant bladder toxicity and reduce the impact of this outcome on prostate cancer survivors.
Year:
2025
Collaborators (22)
Montserrat Garcia-Closas
Professor of Epidemiology
Institute of Cancer Research
William A. Hall
-
Barbara Avuzzi
Fondazione IRCCS Istituto Nazionale dei Tumori
Andriy Derkach
Associate Attending Biostatistician
Memorial Sloan Kettering Cancer Center
Jane Shortall
The University of Manchester
Louise Brinton
Branch Chief
National Cancer Institute
Stephen Chanock
National Institutes of Health
Brian Marples
Dr. Sidney H. and Barbara L. Sobel Professor in Radiation Oncology
University of Rochester Medical Center
Harry Ostrer
Professor
Yeshiva University Albert Einstein College of Medicine
Alan Mcwilliam
University of Manchester
Marcel van Herk
The University of Manchester
Paul Auer
Professor
Medical College of Wisconsin
Christopher Talbot
Professor of Radiotherapy Genetics
University of Leicester
Michelle C. Janelsins
Division Chief and Professor
University of Rochester Medical Center
Tiziana Rancati
Researcher
Fondazione IRCCS Istituto Nazionale dei Tumori
Ananya Choudhury
The University of Manchester
Edward Messing
Professor
University of Rochester Medical Center
Thomas Ahearn
Staff Scientist
National Cancer Institute
Catharine West
The University of Manchester
Seth Wiafe
Assistant Professor
Loma Linda University
Andrew Morris
The University of Manchester
Sarah Kerns
Associate Professor
Medical College of Wisconsin
Make your next move.
Prepare your application
Review drafts before you send them.